The use of tranexamic acid in the management of injured patients at risk of hemorrhage: a systematic review and meta-analysis and an Eastern Association for the Surgery of Trauma Practice Management Guideline
- PMID: 40956301
- DOI: 10.1097/TA.0000000000004773
The use of tranexamic acid in the management of injured patients at risk of hemorrhage: a systematic review and meta-analysis and an Eastern Association for the Surgery of Trauma Practice Management Guideline
Abstract
Background: The use of tranexamic acid in trauma patients at risk for hemorrhage remains controversial. This guideline evaluates the use of tranexamic acid in two clinical settings, the prehospital environment and the inpatient setting. In addition, this PMG evaluates the use TXA in specific populations and at different dosages and evaluates the potential risks associated with its use.
Methods: Using the Grading of Recommendations Assessment, Development and Evaluation methodology, an EAST working group conducted a systematic review using MEDLINE, EMBASE, and COCHRANE CENTRAL. Articles in English from 2000 through 2023 were considered in evaluating four PICO questions relevant to the use of TXA in injured trauma patients at risk of hemorrhage (defined as patients with a systolic blood pressure (SBP) ≤90 mm Hg or a heart rate ≥110/min or suspicion for active hemorrhage).
Results: Thirty studies were identified for qualitative analysis, of which 24 met criteria for meta-analysis. TXA was associated with a significant reduction in 24-hour mortality in both prehospital (log risk ratio, -0.29; 95% confidence interval, -0.53 to -0.05; p = 0.02) and in-hospital settings (-0.38[-0.69, -0.06]; p = 0.02). A similar benefit was observed at 30-days across both settings (prehospital: -0.18[-0.35, -0.00]; p = 0.05, in-hospital: -0.24[-0.40, -0.07]; p = 0.01). In patients with SBP ≤75 mm Hg, TXA reduced mortality, but this was not found to be significant (-0.18 [-0.46, 0.09]; p = 0.20). The incidence of vaso-occlusive events did not differ between groups in either setting. Moreover, a large heterogeneity regarding TXA dosing regimens and comparison groups across studies was observed.
Conclusion: Based on current available evidence, we conditionally recommend for the routine use of TXA in the prehospital and in-hospital settings. We cannot recommend for or against the use of an initial higher dose of bolus TXA. Finally, we conditionally recommend for the routine use of TXA in patients with severe hypotension.
Level of evidence: Level 1: Meta-analysis.
Keywords: TXA; blood; hemorrhage; resuscitation; tranexamic acid.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79–87.
-
- Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015;70(Suppl 1):50–3, e18.
-
- Mannucci Pier M. Hemostatic drugs. N Engl J Med. 339(4):245–253.
-
- Franchini M, Mannucci PM. Adjunct agents for bleeding. Curr Opin Hematol. 2014;21(6):503–508.
-
- Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015;261(2):390–394.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous